Shares of Cue Biopharma (CUE) were oddly volatile today – on below average volume, no less. What gives?
I’m convinced it’s simply profit-taking and some jitters ahead of tomorrow’s presentation at the Jefferies Virtual Healthcare Conference, during which management will likely provide the highly anticipated interim data from its Phase 1 study for CUE-101.
First things first, the profit-taking is understandable.
After all, shares are up 250% in the last year and 133% in the last six months. So can you blame anyone during these times for booking some gains?
(In the infamous words of music-legend Shaggy, though, “It wasn’t me.” As I outlined in my April 21 update, I’m letting it ride).
However, any selling due to jitters over “bad” data are categorically unfounded.
Here’s the proof and why I (still) expect any data shared tomorrow to be positive…
Want to keep reading? No problem! All you have to do is sign up for FREE here as a registered user.
By doing so, you agree to receive periodic research updates from DTR and only DTR.
We will never rent, sell or share your info.